KAPA shares will consolidate to meet NYSE American listing requirements, trading resumes under the same ticker.
Kairos Pharma will implement a 1-for-7 reverse stock split effective September 1, 2026, before market open. The move aims to maintain compliance with NYSE American listing standards, the company stated.
Each seven existing shares of KAPA will convert into one new share. The stock will continue trading under the same ticker symbol on the NYSE American exchange. No changes to the company’s fundamentals or operations are expected from the split.
The reverse split follows a period of low share price, which triggered regulatory concerns. Similar actions are common among small-cap firms seeking to avoid delisting.